{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'The Investigator (or designee) must call and talk to the subject at least weekly in between the', 'screening and baseline visits; alternative forms of interactive communication such as returned', 'email and cellular text correspondence are acceptable. During all calls, the Investigator (or', \"designee) will assess the subject's overall wellbeing, discuss compliance (if applicable), proper\", 'recording of attack details (if applicable), or any usability issues with the e-diary. A weekly', 'phone call may be omitted if the subject records an attack as the Investigator must call and', 'confirm or reject the attack.', 'If a subject has a normal C4 level (as is the case in a small percentage of subjects with HAE)', 'drawn at the screening visit, the site may take another sample for C4 level assessment, during an', 'attack. A normal C4 level, when drawn during an attack, excludes the subject from study', 'participation.', 'If a subject has a normal C4 at the screening visit and it is desired to utilize a family history of', 'C1-INH deficiency to establish an HAE diagnosis for eligibility, the Investigator should', \"document this as a source file note based on either the Investigator's personal knowledge (ie, if a\", 'relative of the screening subject is also a patient of the same Investigator/practice) or interaction', 'with medical staff of the treatment facility where the relative receives HAE care, who confirms', 'the diagnosis. No historical laboratory documentation on the relative should be collected in the', 'source documents.', 'A SERPING-1 mutation known, or likely, to be associated with HAE Type I or II is acceptable', 'to confirm the diagnosis of HAE.', 'For a C1-INH functional level that is between 50% and the LLN (74%), the site may draw', 'another C1-INH functional level or, if desired, have a SERPING-1 gene mutational analysis', 'performed by the central laboratory. A C1-INH functional level < 50% or a SERPING-1', 'mutation known, or likely, to be associated with HAE Type I or II, as assessed by the central', 'laboratory, is acceptable to confirm the diagnosis of HAE.', 'Blood for possible SERPING-1 gene sequencing may be drawn at the Screening visit but', 'analyzed in the period between the screening and baseline visits only if required for eligibility', '(normal C4 at screening or a C1-INH level between 50% and the LLN [74%]).', 'Subjects who are deemed ineligible for the study will return their e-diary to the study site.', 'Rescreening of ineligible subjects, where there is a reasonable expectation that the subject will', 'become eligible, will be approved or denied on a case-by-case basis by the Sponsor Medical', 'Monitor. Retesting of specific assessments within the screening period without entirely', 'rescreening a subject may be permitted. Additionally, the Investigator must gain Sponsor', 'approval to enroll subjects who are not randomized within 10 weeks of the screening visit; this', 'may require screening labs to be redrawn. Subjects will not be permitted to rescreen if they did', 'not meet the HAE attack requirements during the run-in period.', 'A screening failure CRF page will be completed for those subjects who do not proceed with', 'study dosing, recording the reason for screen failure.', 'AEs and concomitant medications will be recorded if reported during this period.', '64']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', '10.3.3.', 'Part 1', '10.3.3.1. Baseline Visit (Day 1)', 'Subjects who meet all study eligibility criteria, and who agree to participate will be asked to', 'return for a scheduled Day 1 visit, to be held 70 days or less from the screening visit.', 'Before any study drug is administered the following assessments will be completed:', 'Administration of EQ-5D-5L, AE-QoL, TSQM, and WPAI questionnaires. Where', 'possible, the questionnaires should be completed by the subject prior to other', 'assessments to prevent influencing subject perceptions.', 'Review of inclusion and exclusion criteria, medical and medication history (including', 'HAE medical and medication history) and prohibited medications', 'Subject weight', 'Vital signs (blood pressure, temperature, respiratory rate, and pulse rate)', '12-lead ECG (in triplicate)', 'Complete physical examination', 'Blood collection for clinical chemistry, hematology, and coagulation, C1-INH', 'antigenic level, complement 3 (C3), Troponin I and Troponin T, NGAL, HLA typing,', 'and CK-MB', 'PK and PD plasma samples', 'Optional blood collection for exploratory pharmacogenomics testing (provided a', 'separate informed consent/assent has been obtained; sample can be drawn at any', 'visit)', 'Urine collection for urinalysis, possible reflex testing for abnormal GGT, AST, or', 'ALT and urine pregnancy test for female subjects of childbearing potential. A', 'negative urine pregnancy result must be recorded for the subject to be dosed.', 'Review of concomitant medications and AEs', 'e-Diary instruction and review', 'Randomization, study drug accountability and dispensing. It is preferred that', 'randomization occur after all Baseline assessments have been completed.', 'After completion of the above bulleted items, the first dose of study drug may be administered in', 'the clinic (see Section 9.3.2) or administered at home on the day of the visit. Day 1 of the study', 'is defined as the day in which subjects take the first dose of study drug.', 'During the Part 1 dosing period, Investigators will contact subjects to confirm all HAE attacks', 'recorded in the e-diary within approximately 2 business days of the end of the attack. Moreover,', 'any noncompliance will warrant contact with the subject.', 'The Investigator (or designee) must call and talk to the subject at least weekly; alternative forms', 'of interactive communication such as returned email and cellular text correspondence are', \"acceptable. During all calls, the Investigator (or designee) will assess the subject's overall\", '65']\n\n###\n\n", "completion": "END"}